Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway

International Immunopharmacology

Volumn 17, Issue 3, 2013, Pages 585-592

  Huang, Shuling ^a   Chen, Min ^a   Ding, Xiwei ^a   Zhang, Xiaoqi ^a   Zou, Xiaoping ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Antitumor effects; Chemoresistance; Gastric cancer; IL 6 STAT3 pathway; Proton pump inhibitor

Indexed keywords

CISPLATIN; CYCLIN D1; INTERLEUKIN 6; LIPOCORTIN 5; PANTOPRAZOLE; PROTEIN BCL 2; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG SELECTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IC 50; LOW DRUG DOSE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

ANTITUMOR EFFECTS; CHEMORESISTANCE; GASTRIC CANCER; IL-6/STAT3 PATHWAY; PROTON PUMP INHIBITOR;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-6; PROTON PUMP INHIBITORS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 84883538789     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.07.021     Document Type: Article

References (30)

1. +-ATPase in drug-resistant human breast carcinoma cell lines Biochem Pharmacol 57 1999 1037 1046 (Pubitemid 29168552)
2. +-ATPases as a new strategy against cancer Cancer Res 67 2007 10627
3. +-ATPase c subunit gene (ATP6L) in response to anticancer agents J Biol Chem 277 2002 36534 36543
4. V. Boparai, J. Rajagopalan, and G. Triadafilopoulos Guide to the use of proton pump inhibitors in adult patients Drugs 68 2008 925 947 (Pubitemid 351652922)
5. +-ATPase Biochem Biophys Res Commun 196 1993 699 706 (Pubitemid 23337664)
6. F. Luciani, M. Spada, A. De Milito, A. Molinari, L. Rivoltini, and A. Montinaro Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs J Natl Cancer Inst 96 2004 1702 1713 (Pubitemid 39585639)
7. A. De Milito, E. Iessi, M. Logozzi, F. Lozupone, M. Spada, and M.L. Marino Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species Cancer Res 67 2007 5408
8. M. Chen, X. Zou, H. Luo, J. Cao, X. Zhang, and B. Zhang Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells Cell Biol Int 33 2009 1008 1019
9. M. Chen, S.L. Huang, X.Q. Zhang, B. Zhang, H. Zhu, and V.W. Yang Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo J Cell Biochem 113 7 2012 2474 2487
10. A. De Milito, R. Canese, M.L. Marino, M. Borghi, M. Iero, and A. Villa pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity Int J Cancer 127 2010 207 219
11. M. Yeo, D.K. Kim, Y.B. Kim, T.Y. Oh, J.E. Lee, and S.W. Cho Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells Clin Cancer Res 10 2004 8687
12. R.R. Kedika, R.F. Souza, and S.J. Spechler Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications Dig Dis Sci 54 2009 2312 2317
13. O. Handa, N. Yoshida, N. Fujita, Y. Tanaka, M. Ueda, and T. Takagi Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors Inflamm Res 55 2006 476 480
14. T. Sasaki, M. Yamaya, H. Yasuda, D. Inoue, M. Yamada, and H. Kubo The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells Eur J Pharmacol 509 2005 201 210 (Pubitemid 40279079)
15. S. Hashioka, A. Klegeris, and P.L. Mcgeer Proton pump inhibitors reduce interferon-γ-induced neurotoxicity and STAT3 phosphorylation of human astrocytes Glia 59 2011 833 840
16. T. Tanigawa, T. Watanabe, K. Higuchi, H. Machida, H. Okazaki, and H. Yamagami Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-α and interleukin-1β induced by lipopolysaccharide and Helicobacter pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-κB and extracellular signal-regulated kinase J Clin Biochem Nutr 45 2009 86
17. + ionophore Inflamm Res 56 2007 105 111 (Pubitemid 46570795)
18. H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 9 2009 798 809
19. J. Horn The proton-pump inhibitors: similarities and differences Clin Ther 22 2000 266 280 (Pubitemid 30213134)
20. M. Chen, S.L. Huang, X.Q. Zhang, B. Zhang, H. Zhu, and V.W. Yang Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo J Cell Biochem 113 2012 2474 2487
21. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer-related inflammation Nature 454 2008 436 444
22. T. Ara, L. Song, H. Shimada, N. Keshelava, H.V. Russell, and L.S. Metelitsa Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells Cancer Res 69 2009 329
23. S. Grivennikov, E. Karin, J. Terzic, D. Mucida, G.Y. Yu, and S. Vallabhapurapu IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer Cancer Cell 15 2009 103 113
24. J. Bollrath, T.J. Phesse, V.A. Von Burstin, T. Putoczki, M. Bennecke, and T. Bateman gp130-Mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis Cancer Cell 15 2009 91 102
25. H. Ogura, M. Murakami, Y. Okuyama, M. Tsuruoka, C. Kitabayashi, and M. Kanamoto Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction Immunity 29 2008 628 636
26. H. Izumi, T. Torigoe, H. Ishiguchi, H. Uramoto, Y. Yoshida, and M. Tanabe Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy Cancer Treat Rev 29 2003 541 549 (Pubitemid 37428326)
27. S. Huang, M. Chen, Y. Shen, W. Shen, H. Guo, and Q. Gao Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells Cancer Lett 315 2 2012 198 205
28. K. Spiekermann, M. Pau, R. Schwab, K. Schmieja, S. Franzrahe, and W. Hiddemann Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells Exp Hematol 30 2002 262 271 (Pubitemid 34203733)
29. S.R. Walker, E.A. Nelson, L. Zou, M. Chaudhury, S. Signoretti, and A. Richardson Reciprocal effects of STAT5 and STAT3 in breast cancer Mol Cancer Res 7 2009 966 976
30. D. Televantou, G. Karkavelas, P. Hytiroglou, S. Lampaki, G. Iliadis, and P. Selviaridis DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome Pathol Oncol Res 19 2 2013 329 343